WAVE Life Sciences (WVE) Tops Q4 EPS by 2c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street lower on AI spending jitters; oil prices rebound
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Brent hits five-month high on escalating Middle East conflict
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
- US orders diplomats to depart Saudi Arabia amid Houthi strikes
Wave Life Sciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
March 4, 2021 7:00 AM ESTStrong execution in 2020 sets stage for advancing five clinical programs and novel ADAR editing modality in 2021
Data from ongoing PRECISION-HD and OLE clinical trials for Huntingtons disease on track for end of 1Q 2021
Moving towards first patient dosing in three clinical trials with pipeline candidates incorporating PN chemistry: WVE-003 (SNP3), WVE-004 (C9orf72) and WVE-N531 (Exon 53)
Cash runway expected into 2Q 2023
Wave to host investor conference call and webcast at 8:00 a.m. ET today
CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Wave... More



